Danaher reported Q1 2026 GAAP EPS of $1.45 and adjusted EPS of $2.06, with revenue up 3.5% to $6.0 billion but slightly below some external estimates around $5.95–$6.06 billion. The stock reaction was muted, with shares largely unchanged after the report, reflecting a mixed but stable outlook and modest core growth.
About Danaher Corporation
Danaher Corporation (NYSE: DHR) is a global life sciences and diagnostics company headquartered in Washington, D.C., focused on tools, technologies, and services that enable faster, more accurate diagnosis and the development of life‑changing therapies. Founded in 1969, the group operates through leading businesses in biotechnology, life sciences, and diagnostics, serving biopharma, clinical, and research customers worldwide.
Danaher is powered by the Danaher Business System, a continuous‑improvement framework used to drive innovation, productivity, and operational excellence across its approximately 60,000 associates. The company emphasizes recurring revenue from consumables and services tied to installed instrument bases in labs and hospitals.
While the press release does not disclose current market cap, recent pricing implies a large‑cap profile well above $150 billion, and management highlights strong free cash flow generation as a key financial strength.
Top Financial Highlights
- Q1 2026 revenues increased 3.5% year over year to $6.0 billion from $5.74–$5.74 billion in Q1 2025, with non‑GAAP core revenue up 0.5%.
- GAAP net earnings were $1.0 billion, up from $954 million a year earlier, reflecting resilient profitability.
- GAAP diluted EPS came in at $1.45, versus $1.32 in Q1 2025.
- Non‑GAAP adjusted diluted EPS grew 9.5% to $2.06 from $1.88, beating several external EPS estimates of around $1.94–$1.96.
- Gross profit rose to $3.59 billion on sales of $5.95–$5.95 billion, implying a gross margin of roughly 60%.
- Operating profit increased to $1.34 billion, supported by disciplined spending on SG&A ($1.86 billion) and R&D ($387 million).
- Operating cash flow was $1.32 billion, with non‑GAAP free cash flow of $1.09 billion, roughly matching the prior year’s $1.06 billion.
- Biotechnology segment total sales grew 11.5%, with core sales up 7.0%, driven by strength in bioprocessing.
- Life Sciences segment sales increased 3.5%, with core growth of 0.5%, reflecting steady demand in research and analytical instruments.
- Diagnostics segment sales declined 1.5%, with core sales down 4.0%, impacted by a lighter‑than‑typical respiratory testing season at Cepheid.
- Management raised full‑year 2026 adjusted diluted EPS guidance to $8.35–$8.55 from $8.35–$8.50, signaling confidence in earnings momentum.
- For Q2 2026, Danaher expects total company non‑GAAP core revenue to grow in the low‑single‑digit range year over year.
- For full year 2026, Danaher continues to guide for non‑GAAP core revenue growth of 3%–6%, with total company core growth supported by mid‑single‑digit growth in Biotechnology and modest gains in Diagnostics and Life Sciences.
- Operating cash generation remains a priority, with guidance implying adjusted operating margin around 26.5% in Q2 2026 and an effective tax rate of about 17% for the year.
- Danaher announced its intention to acquire Masimo Corporation, a leading pulse oximetry and patient‑monitoring company, to enhance its acute‑care monitoring portfolio and leverage Danaher Business System (DBS) execution and global scale.
DANAHER CORPORATION AND SUBSIDIARIES
Beat or Miss?
| Metric | Reported | Difference / Analysis |
| Revenue | $6.0B (Danaher) | Slightly below external figures citing about $5.95–$6.06B; effectively in line with modest top‑line expectations. |
| GAAP Diluted EPS | $1.45 | Higher than prior year $1.32, but external consensus was framed mainly on adjusted EPS. |
| Adjusted Diluted EPS (Non‑GAAP) | $2.06 | Beat several consensus estimates of roughly $1.94–$1.96, a positive earnings surprise of about 6%. |
| Core Revenue Growth (Non‑GAAP) | 0.5% | Indicates modest underlying demand; investors viewed this as stable but not exciting. |
| Operating Cash Flow | $1.32B | Slightly above prior year $1.30B, confirming strong cash conversion. |
What Leadership Is Saying?
“Our team executed well in the first quarter, which enabled us to accelerate innovation, drive productivity gains, and deliver nearly 10% adjusted EPS growth. On the top line, we continued on a steady recovery path with strength in Bioprocessing and better‑than‑expected performance in Life Sciences largely offsetting the impact of a lighter‑than‑typical Q1 respiratory season at Cepheid.” – Rainer M. Blair, President and Chief Executive Officer
“We were also pleased to announce our intention to acquire Masimo Corporation, a leading provider of mission‑critical pulse oximetry and patient monitoring solutions in acute care settings. We believe there are clear opportunities to enhance Masimo’s performance through DBS and our global scale, while our strong balance sheet and free cash flow generation provide additional capacity for value‑creating capital deployment.” – Rainer M. Blair, speaking to strategic and financial positioning
Historical Performance
Danaher YoY Metrics
| Category | Q1 2026 | Q1 2025 | Change (%) |
| Revenue / Sales | $5,951–$6,000M | $5,741M | ≈ +3.5% revenue growth. |
| Net Income | $1,029M | $954M | ≈ +7.9% improvement in net earnings. |
| Operating Profit | $1,344M | $1,274M | ≈ +5.5% increase in operating profit. |
| Gross Margin (implied) | ~60% (3,591 / 5,951) | ~61% (3,511 / 5,741) | Slight margin compression, but still robust. |
| Operating Cash Flow | $1,322M | $1,299M | Modest increase in cash generation. |
Historical Performance of Peers (YoY Snapshot)
Below is an illustrative peer comparison using other large life‑science and diagnostics players’ most recent year‑over‑year quarterly trends as reported around similar timeframes, where available.
| Company / Category | Q1 2026 (or latest) | Q1 2025 (or prior year) | Change (%) / Notes |
| Danaher – Revenue | $5.95–$6.0B | $5.74B | ≈ +3.5% top‑line growth. |
| Danaher – Net Income | $1.03B | $0.95B | ≈ +7.9% YoY earnings growth. |
| Thermo Fisher (example)* – Revenue | High‑single‑digit reported growth in recent quarter. | Prior‑year quarter with mid‑single‑digit growth. | Trend: resilient demand and steady growth. |
| Thermo Fisher – Net Income | Management indicates stable to improving profitability. | Lower earnings base a year earlier. | Trend: margin support from mix and scale. |
How the Market Reacted?
External commentary describes Q1 2026 as a mixed but solid quarter: adjusted EPS beat expectations, while revenue growth and core growth stayed modest at 3.5% and 0.5%, respectively. Despite the earnings beat, the stock’s immediate reaction was muted, with shares “largely unchanged” after the report, suggesting investors saw results as stable but not a major inflection.
The slight drag from Cepheid respiratory testing and only modest core growth tempered enthusiasm, even as guidance for full‑year adjusted EPS edged higher. Overall sentiment around the release can be characterized as cautiously constructive, with investors recognizing resilient profitability and cash flow but still waiting for a stronger acceleration in underlying demand.
